Generalised Anxiety Disorder (GAD)

1. Clinical Overview

Summary

Generalised Anxiety Disorder (GAD) is a chronic mental health condition characterised by excessive, uncontrollable worry about multiple aspects of everyday life (health, work, finances, family, relationships) persisting for at least 6 months. Unlike normal worry, GAD worry is disproportionate to actual circumstances, difficult to control, and accompanied by significant physical and cognitive symptoms. [1,2]

GAD affects approximately 5-6% of the population during their lifetime, with a 2:1 female predominance. [3,25,26] The condition typically begins in early adulthood (peak onset 30s-40s), though childhood and adolescent onset is common. GAD is highly comorbid with major depressive disorder (60% overlap), other anxiety disorders, and substance use disorders. [4,5,28]

The hallmark feature is intolerance of uncertainty — patients find ambiguous situations unbearable and engage in excessive worry as a maladaptive coping strategy. This creates a self-perpetuating cycle: worry → temporary relief → increased anxiety → more worry. [6]

Management follows a stepped-care approach: psychoeducation and lifestyle interventions → low-intensity CBT (guided self-help) → high-intensity CBT and/or pharmacotherapy (SSRIs: sertraline, escitalopram) → specialist input with SNRIs or pregabalin for treatment-resistant cases. [1,22,30] Cognitive-behavioural therapy (CBT) is first-line and shows robust, sustained efficacy. [7,8]

The GAD-7 (7-item Generalized Anxiety Disorder scale) is a validated screening and severity monitoring tool, with scores ≥10 indicating moderate anxiety warranting intervention. [9]

---

Key Facts at a Glance

---

Clinical Pearls

"GAD = Worry About Everything, All the Time" GAD is generalised — patients worry excessively about multiple areas of life, not confined to a single domain (unlike specific phobias or health anxiety).

"The Worry Feels Uncontrollable" A key diagnostic feature: patients describe worry as difficult or impossible to stop, unlike normal worry which people can redirect.

"CBT Is First-Line Before Medication" NICE guidelines recommend psychological therapy (CBT) as first-line or alongside medication, not after medication failure. [1]

"Sertraline Is the First-Choice SSRI" Sertraline is preferred due to robust evidence, good tolerability, and cost-effectiveness. Escitalopram is an alternative. [1,10]

"Start SSRIs Low — They Can Transiently Worsen Anxiety" Begin sertraline at 25 mg (below therapeutic dose) for 1 week, then increase to 50 mg, to minimise activation syndrome (initial anxiety, agitation). [1]

"Avoid Benzodiazepines Long-Term" Benzodiazepines (diazepam, lorazepam) work acutely but cause tolerance, dependence, cognitive impairment, and rebound anxiety on withdrawal. Use only short-term (≤2-4 weeks) in crisis. [1]

"Always Screen for Depression" 60% of GAD patients have comorbid major depression. Use PHQ-9 alongside GAD-7. [4]

"Pregabalin Is Licensed for GAD in Europe" Pregabalin (150-600 mg/day) is effective and licensed for GAD, though less commonly first-line due to sedation and dependence concerns. [11,12]

"Relapse Is Common After Stopping Treatment" Continue effective medication for ≥12 months after symptom remission to reduce relapse risk. [1]

---

Why This Matters Clinically

GAD is common (1 in 20 lifetime risk), chronic (average duration 10-20 years if untreated), and disabling (equivalent functional impairment to diabetes or arthritis). [3,25,26] It is frequently under-recognised in primary care, with patients presenting primarily with somatic complaints (fatigue, muscle pain, insomnia, headaches) rather than explicitly reporting worry. [13,21]

Evidence-based treatment — particularly CBT — is highly effective, with 60-70% response rates and sustained benefits at 1-2 year follow-up. [7,8,31] Pharmacotherapy (SSRIs, SNRIs) shows similar acute efficacy but higher relapse rates after discontinuation. [10,31,32]

Early recognition and treatment improves quality of life, prevents progression to depression, reduces disability, and avoids chronic benzodiazepine use. [1,30,33]

---

2. Epidemiology

Incidence & Prevalence

Global Burden

• Global prevalence: ~4-6.2% across cultures (similar rates in high-income and low-income countries) [3,25,28]
• Disability: GAD contributes significantly to global disease burden; functional impairment equivalent to major chronic medical conditions [13,25]
• Economic cost: Lost productivity, healthcare utilisation, comorbidity treatment costs substantial [28]

---

Risk Factors

Protective Factors

• Strong social support networks
• Secure attachment in childhood
• Regular physical exercise
• Effective stress management skills

---

3. Pathophysiology

GAD arises from a complex interplay of neurobiological, cognitive, and environmental factors. No single mechanism explains the condition; instead, multiple systems interact to produce the clinical phenotype.

---

3.1 Neurobiological Factors

---

3.2 Structural and Functional Neuroimaging

Summary: GAD involves hyperactive threat-detection circuits (amygdala, insula) combined with impaired top-down regulatory control (PFC, ACC). [15]

---

3.3 Genetic and Familial Factors

• Heritability: ~30% based on twin studies [14,27]
• Familial aggregation: First-degree relatives of GAD patients have 5-6× increased risk [14,27]
• Candidate genes: Polymorphisms in serotonin transporter (5-HTTLPR), COMT (catechol-O-methyltransferase), BDNF (brain-derived neurotrophic factor) — though effect sizes small and inconsistent [14,27]
• Gene-environment interaction: Genetic vulnerability + childhood adversity → highest risk [14,27]

---

3.4 Cognitive and Psychological Mechanisms

Intolerance of Uncertainty (IU)

The central cognitive model of GAD: individuals with GAD have abnormally low tolerance for ambiguous or uncertain situations. [6]

• Belief: "Uncertainty is dangerous and must be resolved"
• Behaviour: Excessive information-seeking, reassurance-seeking, avoidance of uncertain situations
• Paradox: Worry is perceived as a way to "prepare" for negative outcomes, but actually maintains anxiety
• Target of CBT: Increase tolerance for uncertainty; reduce excessive preparation behaviours

Positive and Negative Beliefs About Worry

• Positive meta-cognitive beliefs: "Worry helps me solve problems"; "Worry prevents bad things happening" → maintains worry
• Negative meta-cognitive beliefs: "I can't control my worry"; "Worry will harm me physically/mentally" → increases distress about worrying [6]

Cognitive Biases

---

3.5 Developmental Factors

• Childhood temperament: Behavioural inhibition (shy, withdrawn children) predicts later anxiety disorders [14]
• Attachment: Insecure attachment (particularly anxious-ambivalent) associated with adult GAD [14]
• Parenting: Overprotective/controlling parenting → reduced autonomy → intolerance of uncertainty [14]
• Childhood adversity: Physical/emotional abuse, neglect, parental mental illness, bullying all increase risk [5,14]

---

4. Clinical Presentation

4.1 Diagnostic Criteria

DSM-5 Criteria for Generalised Anxiety Disorder [2]

A. Excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities (such as work or school performance).

B. The individual finds it difficult to control the worry.

C. The anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms having been present for more days than not for the past 6 months):

1. Restlessness or feeling keyed up or on edge
2. Being easily fatigued
3. Difficulty concentrating or mind going blank
4. Irritability
5. Muscle tension
6. Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep)

Note: Only one symptom is required in children.

D. The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

E. The disturbance is not attributable to the physiological effects of a substance (e.g., drug of abuse, medication) or another medical condition (e.g., hyperthyroidism).

F. The disturbance is not better explained by another mental disorder (e.g., panic disorder, social anxiety disorder, OCD, PTSD, separation anxiety disorder, illness anxiety disorder, schizophrenia).

---

ICD-11 Criteria (6B00 Generalised Anxiety Disorder)

• Marked symptoms of anxiety (apprehension, worry, autonomic arousal)
• Not restricted to particular environmental circumstances (i.e., "generalised")
• Symptoms present most days for at least several months
• Symptoms cause significant distress or functional impairment

---

4.2 Core Clinical Features

---

4.3 Physical (Somatic) Symptoms

Clinical Pearl: Patients with GAD often present to primary care or medical specialists with somatic complaints (fatigue, muscle pain, insomnia, IBS, headaches) rather than explicitly reporting psychological symptoms. Always screen for anxiety when physical symptoms lack clear organic cause. [13]

---

4.4 Cognitive Symptoms

• Difficulty concentrating ("mind goes blank")
• Impaired memory (especially working memory)
• Indecisiveness
• Catastrophic thinking ("What if the worst happens?")
• Excessive planning and "mental preparation"

---

4.5 Behavioural Features

• Reassurance-seeking: Repeated questions to family/friends/doctors
• Checking behaviours: Repeatedly checking doors, appliances, children's safety
• Avoidance: Avoiding situations that trigger uncertainty (e.g., travel, social events)
• Procrastination: Paralysed by worry; difficulty initiating tasks
• Restlessness: Pacing, fidgeting, inability to sit still

---

4.6 Red Flags and Safety Concerns

[!CAUTION] RED FLAGS — IMMEDIATE ASSESSMENT REQUIRED

• Suicidal ideation or plan (especially if comorbid depression)
• Severe functional impairment (unable to work, care for self/family)
• Comorbid substance use disorder (alcohol, benzodiazepines, opioids)
• Psychotic symptoms (hallucinations, delusions) → reconsider diagnosis (psychotic disorder, severe depression, substance-induced)
• Acute severe anxiety/panic not responding to initial management → consider crisis team/admission
• High-risk medical comorbidities (unstable cardiovascular disease, uncontrolled diabetes — anxiety can worsen control)

---

5. Clinical Examination

5.1 Mental State Examination (MSE)

---

5.2 Physical Examination

Purpose: Exclude organic causes of anxiety (hyperthyroidism, cardiac arrhythmia, anaemia, hypoglycaemia)

---

6. Investigations

6.1 Screening and Severity Assessment Tools

GAD-7 (Generalized Anxiety Disorder-7) [9]

Validated, brief (7-item) screening and severity tool

The GAD-7 is a psychometrically robust self-report questionnaire designed for rapid screening and severity assessment of generalized anxiety disorder in both clinical and research settings. [9,20] It was developed using diagnostic criteria from the DSM-IV and has demonstrated excellent reliability and validity across diverse populations. [9]

Psychometric Properties:

• Internal consistency: Cronbach's α = 0.92 (excellent) [9]
• Test-retest reliability: Intraclass correlation = 0.83 [9]
• Convergent validity: Strong correlation with other anxiety scales (Beck Anxiety Inventory r=0.72) [9]
• Discriminant validity: Moderate correlation with depression scales (PHQ-9 r=0.64), confirming it measures anxiety specifically [9]
• Factor structure: Unidimensional (all items load on single anxiety factor) [9]
• Cultural validity: Validated in > 40 languages; performs well across ethnic groups [20]

Questions ask: "Over the last 2 weeks, how often have you been bothered by the following problems?"

1. Feeling nervous, anxious, or on edge
2. Not being able to stop or control worrying
3. Worrying too much about different things
4. Trouble relaxing
5. Being so restless that it's hard to sit still
6. Becoming easily annoyed or irritable
7. Feeling afraid as if something awful might happen

Scoring: 0 (Not at all) — 1 (Several days) — 2 (More than half the days) — 3 (Nearly every day)

GAD-7 ≥10: Sensitivity 89%, Specificity 82% for GAD diagnosis [9]

Clinical Utility:

• Screening: Takes 1-2 minutes; can be self-administered or delivered verbally
• Diagnosis: ≥10 indicates probable GAD warranting further diagnostic interview
• Severity monitoring: Repeat every 2-4 weeks during treatment to track response
• Treatment response: ≥5-point reduction indicates clinically meaningful improvement [9,20]
• Remission: Score less than 5 indicates symptomatic remission [20]

Additional use: Monitor treatment response — repeat GAD-7 every 2-4 weeks during treatment

Limitations:

• Not a diagnostic tool (requires clinical interview for definitive diagnosis)
• Cannot distinguish GAD from other anxiety disorders (panic, social anxiety)
• May be elevated in depression, PTSD, adjustment disorders
• Cultural considerations: some items (e.g., "irritability") may be interpreted differently across cultures [20]

---

PHQ-9 (Patient Health Questionnaire-9)

Always screen for comorbid depression (60% overlap with GAD) [4]

9-item tool for depression severity; scoring identical to GAD-7 (0-3 per item, max 27)

• 0-4: Minimal
• 5-9: Mild
• 10-14: Moderate
• 15-19: Moderately severe
• 20-27: Severe

Item 9 ("Thoughts that you would be better off dead or hurting yourself") — if scored > 0, assess suicide risk immediately

---

6.2 Exclude Organic Causes

---

6.3 Exclude Differential Diagnoses

Note: Comorbidity is common — GAD often coexists with depression, other anxiety disorders, and substance use.

---

7. Management

7.1 Management Algorithm: NICE Stepped Care [1]

           GENERALISED ANXIETY DISORDER MANAGEMENT
                         ↓
┌──────────────────────────────────────────────────────────────┐
│  STEP 1: RECOGNITION, ASSESSMENT, PSYCHOEDUCATION            │
├──────────────────────────────────────────────────────────────┤
│  Recognition:                                                 │
│  ➤ Screen with GAD-7 (≥10 = active treatment threshold)     │
│  ➤ Screen for depression with PHQ-9                         │
│  ➤ Assess suicide risk, substance use, functional impact    │
│                                                               │
│  Psychoeducation:                                             │
│  ➤ Explain GAD: excessive worry, physical symptoms, cycle   │
│  ➤ Reassure: common, treatable, not "weak" or "crazy"       │
│  ➤ Discuss treatment options: CBT first-line; medications   │
│                                                               │
│  Active Monitoring (for mild symptoms, GAD-7 5-9):          │
│  ➤ Review in 2-4 weeks                                       │
│  ➤ Provide written information (e.g., NHS anxiety leaflets) │
│  ➤ Lifestyle advice (see below)                             │
└──────────────────────────────────────────────────────────────┘
                         ↓
┌──────────────────────────────────────────────────────────────┐
│  LIFESTYLE INTERVENTIONS (ALL PATIENTS)                      │
├──────────────────────────────────────────────────────────────┤
│  ➤ Regular aerobic exercise (30 min, 5× per week)           │
│    — Evidence shows anxiolytic effect [16]                  │
│  ➤ Sleep hygiene:                                            │
│    • Regular sleep-wake times                                │
│    • Avoid screens 1 hour before bed                         │
│    • Relaxation techniques before sleep                      │
│  ➤ Reduce/eliminate caffeine (coffee, energy drinks)        │
│  ➤ Reduce alcohol (avoid using as anxiolytic — rebound)     │
│  ➤ Structured daily routine                                  │
│  ➤ Social connection (avoid isolation)                       │
│  ➤ Mindfulness apps (Headspace, Calm) — limited evidence    │
│    but low harm [17]                                         │
└──────────────────────────────────────────────────────────────┘
                         ↓
┌──────────────────────────────────────────────────────────────┐
│  STEP 2: LOW-INTENSITY PSYCHOLOGICAL INTERVENTIONS           │
│          (GAD-7 10-14 OR persistent mild symptoms)           │
├──────────────────────────────────────────────────────────────┤
│  ➤ Guided self-help (CBT-based workbooks with practitioner  │
│    support, 6-8 sessions)                                    │
│  ➤ Computerised CBT (cCBT): e.g., Beating the Blues, Fear   │
│    Fighter                                                    │
│  ➤ Psychoeducational groups                                  │
│  ➤ IAPT referral (Improving Access to Psychological         │
│    Therapies) — UK NHS service                               │
│                                                               │
│  Duration: 6-8 weeks                                          │
│  Review: If no improvement → Step 3                          │
└──────────────────────────────────────────────────────────────┘
                         ↓
┌──────────────────────────────────────────────────────────────┐
│  STEP 3: HIGH-INTENSITY INTERVENTIONS                        │
│          (GAD-7 ≥15 OR failure of Step 2)                    │
├──────────────────────────────────────────────────────────────┤
│                                                               │
│  PSYCHOLOGICAL THERAPY (FIRST-LINE) [7,8]:                   │
│  ═══════════════════════════════════════                     │
│  ➤ Individual CBT (12-15 weekly sessions)                   │
│    • Psychoeducation about GAD cycle                         │
│    • Cognitive restructuring (challenge catastrophic         │
│      thinking, overestimation of threat)                     │
│    • Behavioural experiments (test predictions)              │
│    • Intolerance of uncertainty work                         │
│    • Exposure to avoided situations                          │
│    • Relapse prevention                                      │
│                                                               │
│  ➤ Applied relaxation (12-15 sessions)                      │
│    • Progressive muscle relaxation + applied practice        │
│    • Less commonly used than CBT                             │
│                                                               │
│  Efficacy: 60-70% response rate; sustained benefit at       │
│  1-2 year follow-up [7,8]                                    │
│                                                               │
│  ────────────────────────────────────────────────────────    │
│                                                               │
│  PHARMACOLOGICAL THERAPY:                                     │
│  ═══════════════════════                                     │
│                                                               │
│  First-Line: SSRI [1,10]                                     │
│  ─────────────────────                                       │
│  ➤ Sertraline (preferred):                                   │
│    • Start: 25 mg daily × 1 week (reduce activation)        │
│    • Then: 50 mg daily (therapeutic dose)                    │
│    • Titrate: Up to 100-200 mg if needed (max 200 mg)       │
│                                                               │
│  ➤ Escitalopram (alternative):                               │
│    • Start: 5 mg daily × 1 week                              │
│    • Then: 10 mg daily (therapeutic dose)                    │
│    • Max: 20 mg daily                                         │
│                                                               │
│  ⚠️ SSRI Prescribing Cautions:                              │
│    • Warn about activation syndrome (transient worsening     │
│      anxiety, agitation, insomnia in first 1-2 weeks)        │
│    • Review at 2 weeks (safety), 4 weeks, 6-8 weeks         │
│    • Full effect may take 8-12 weeks                         │
│    • Continue for ≥12 months after remission to prevent      │
│      relapse                                                  │
│    • Taper slowly on discontinuation (≥4 weeks) to avoid     │
│      withdrawal syndrome                                      │
│    • Contraindications: MAOI within 14 days; caution in      │
│      epilepsy, bleeding disorders, hepatic impairment        │
│    • Side effects: Nausea, diarrhoea, sexual dysfunction,   │
│      sweating, initial activation                            │
│    • Drug interactions: NSAIDs (bleeding risk), other        │
│      serotonergic drugs (serotonin syndrome), warfarin       │
│                                                               │
│  Second-Line SSRI:                                            │
│  ➤ Paroxetine (20-50 mg) — higher discontinuation syndrome  │
│                                                               │
│  ────────────────────────────────────────────────────────    │
│                                                               │
│  COMBINATION THERAPY:                                         │
│  ═══════════════════                                         │
│  ➤ CBT + SSRI shows best outcomes in moderate-severe GAD    │
│  ➤ Consider if monotherapy insufficient                      │
│                                                               │
│  ────────────────────────────────────────────────────────    │
│                                                               │
│  ⚠️ BENZODIAZEPINES (SHORT-TERM ONLY) [1]:                  │
│  ═══════════════════════════════════════                     │
│  ➤ Use ONLY for ≤2-4 weeks in acute crisis while other      │
│    treatments initiated                                       │
│  ➤ Diazepam 2-5 mg BD-TDS or Lorazepam 0.5-1 mg BD-TDS      │
│  ➤ Risks: Tolerance, dependence, cognitive impairment,      │
│    falls (elderly), rebound anxiety on withdrawal            │
│  ➤ Avoid in: Respiratory disease, sleep apnoea, substance   │
│    use history, elderly                                       │
│  ➤ NEVER prescribe long-term                                 │
│                                                               │
└──────────────────────────────────────────────────────────────┘
                         ↓
┌──────────────────────────────────────────────────────────────┐
│  STEP 4: TREATMENT-RESISTANT GAD / SPECIALIST INPUT          │
│          (Failure of ≥2 adequate trials from Step 3)         │
├──────────────────────────────────────────────────────────────┤
│  Reassess:                                                    │
│  ➤ Confirm diagnosis (rule out bipolar, PTSD, personality   │
│    disorder)                                                  │
│  ➤ Check adherence and adequate dose/duration (SSRI needs   │
│    8-12 weeks at therapeutic dose)                           │
│  ➤ Assess comorbidities (depression, substance use, medical)│
│  ➤ Psychosocial stressors (ongoing trauma, domestic abuse)  │
│                                                               │
│  Specialist pharmacotherapy options:                          │
│  ─────────────────────────────────                           │
│  ➤ SNRI (Serotonin-Noradrenaline Reuptake Inhibitor):       │
│    • Venlafaxine XL 75-225 mg daily                          │
│    • Duloxetine 60-120 mg daily                              │
│    • Monitor BP (venlafaxine can raise BP)                   │
│                                                               │
│  ➤ Pregabalin (licensed for GAD in EU) [11,12]:             │
│    • Start: 150 mg/day (in 2-3 divided doses)                │
│    • Therapeutic: 150-600 mg/day                             │
│    • Mechanism: Voltage-gated calcium channel blocker        │
│      (α2δ subunit) → reduced glutamate/noradrenaline release │
│    • Efficacy: NNT ~5 for response vs placebo                │
│    • Side effects: Sedation, dizziness, weight gain, oedema  │
│    • Risks: Dependence potential (Schedule 3 controlled      │
│      drug in UK); avoid in substance use history             │
│    • Taper slowly on discontinuation                         │
│                                                               │
│  ➤ Mirtazapine 15-45 mg nocte (sedating antidepressant)     │
│                                                               │
│  ➤ Quetiapine 50-300 mg (off-license; sedating; metabolic   │
│    side effects limit use)                                    │
│                                                               │
│  ➤ Buspirone 15-60 mg/day (5-HT1A partial agonist; less     │
│    commonly used; slow onset)                                │
│                                                               │
│  Advanced psychological therapies:                            │
│  ─────────────────────────────────                           │
│  ➤ Metacognitive therapy (MCT) — targets beliefs about      │
│    worry [18]                                                │
│  ➤ Acceptance and Commitment Therapy (ACT)                   │
│  ➤ Psychodynamic therapy (less evidence than CBT)           │
│                                                               │
│  Multidisciplinary input:                                     │
│  ─────────────────────                                       │
│  ➤ Psychiatry referral (complex cases, comorbidity)         │
│  ➤ Clinical psychology (trauma, personality factors)         │
│  ➤ Occupational therapy (functional rehabilitation)          │
│  ➤ Social prescribing (housing, benefits, peer support)     │
│                                                               │
└──────────────────────────────────────────────────────────────┘

---

7.2 Key Evidence for Interventions

Cognitive-Behavioural Therapy (CBT)

• Efficacy: Meta-analyses show NNT 2-3 for response vs waitlist/usual care; 60-70% response rate [7,8,35,36]
• Sustained benefit: Effects maintained at 6-12 month and 1-2 year follow-up (better than medication) [7,8,36]
• Components: Psychoeducation, cognitive restructuring (challenging catastrophic thinking, intolerance of uncertainty), behavioural experiments, exposure, relapse prevention [35,36]
• Delivery formats: Individual (preferred), group, guided self-help, computerised CBT (cCBT) all show efficacy [7,8,36]

SSRIs and SNRIs

• Efficacy: Meta-analyses show SSRIs/SNRIs superior to placebo; NNT 5-6 for response [10,31,32]
• Sertraline: Most evidence; well-tolerated; cost-effective; preferred first-line [1,10,22,30]
• Escitalopram: Alternative SSRI; slightly higher efficacy in some trials but more expensive [10,31]
• SNRIs (venlafaxine, duloxetine): Efficacy similar to SSRIs; used second-line or if comorbid pain [10,31,32]
• Onset: 2-4 weeks for initial benefit; 8-12 weeks for full effect [22,30]
• Duration: Continue ≥12 months after remission; relapse common if stopped early [1,30,33]

Pregabalin

• Efficacy: RCTs show efficacy vs placebo; NNT ~5 for response; onset within 1 week (faster than SSRIs) [11,12,23]
• Licensed: EU/UK for GAD; not FDA-approved for GAD in USA [23]
• Concerns: Sedation, dizziness, weight gain; dependence potential (Schedule 3 controlled drug); less commonly first-line [11,12,23]
• Use: Second-line or in treatment-resistant cases [1,11,12,23]

Benzodiazepines

• Efficacy: Rapid anxiolytic effect (within hours-days) [1]
• Risks: Tolerance develops within 2-4 weeks; dependence; cognitive impairment; falls in elderly; rebound anxiety on withdrawal; overdose risk if combined with alcohol/opioids [1]
• Guideline recommendation: ≤2-4 weeks only in acute crisis while CBT/SSRI initiated [1]
• Long-term use: Associated with worse outcomes; should be avoided [1]

---

7.3 Special Populations

Elderly (65 years)

• Prevalence: 3-6% in community-dwelling elderly; higher in care homes [26,29]
• Presentation: Often somatic complaints; comorbid depression common [26,29]
• CBT: Effective; may need slower pace, larger print materials [19]
• Medication: Start lower doses (e.g., sertraline 25 mg); caution with SNRIs (hypertension, falls risk); avoid benzodiazepines (falls, cognitive impairment) [1,30,33]

Pregnancy and Breastfeeding

• CBT: First-line (no fetal risk) [1,30]
• SSRIs: Sertraline preferred if medication essential (lowest placental transfer; compatible with breastfeeding) [1,30,33]
• Avoid: Benzodiazepines (floppy baby syndrome, neonatal withdrawal); pregabalin (limited safety data) [30,33]
• Shared decision-making: Balance maternal mental health vs fetal risks [30]

Children and Adolescents

• Prevalence: 2-5% in children/adolescents [24,26]
• Presentation: Worry about school performance, friendships, health; excessive reassurance-seeking; physical symptoms (stomach aches, headaches) [24]
• First-line: CBT (family involvement important) [1,24]
• Medication: SSRIs considered if severe/impairing and CBT insufficient; close monitoring for activation/suicidality (black box warning less than 25 years) [1,24,32]

---

7.4 Management of Treatment-Resistant GAD

Definition: Failure to respond to ≥2 adequate trials (adequate dose, adequate duration 8-12 weeks) of evidence-based treatment

Reassessment:

1. Confirm diagnosis (exclude bipolar, PTSD, personality disorder, autism spectrum) [37]
2. Check adherence (medication, therapy attendance) [37]
3. Assess comorbidities (depression, substance use, ADHD, medical illness) [37]
4. Identify psychosocial stressors (ongoing trauma, domestic abuse, housing, finances) [37]

Strategies:

• Switch SSRI to SNRI (or vice versa) [37]
• Add pregabalin to SSRI/SNRI (augmentation) [37]
• Combine CBT + medication if not already tried [36,37]
• Specialist psychological therapy (metacognitive therapy, ACT) [18,37]
• Treat comorbidities (depression, insomnia, substance use) [37]
• Address psychosocial factors (social prescribing, housing support) [37]
• Multidisciplinary team input (psychiatry, psychology, occupational therapy) [37]

---

8. Complications and Comorbidities

8.1 Psychiatric Comorbidities

---

8.2 Physical Complications

---

8.3 Functional Impairment

• Occupational: Reduced productivity; absenteeism; presenteeism (at work but impaired)
• Social: Withdrawal from social activities; relationship strain; loneliness
• Quality of life: Equivalent impairment to major chronic medical conditions (diabetes, arthritis) [13]
• Economic: Lost productivity; healthcare costs; welfare dependency

---

9. Prognosis & Outcomes

9.1 Natural History

---

9.2 Response to Treatment

NNT (Number Needed to Treat):

• CBT vs waitlist: NNT 2-3 [7,8]
• SSRI vs placebo: NNT 5-6 [10]
• Pregabalin vs placebo: NNT ~5 [11,12]

---

9.3 Prognostic Factors

---

10. Evidence & Guidelines

10.1 Key Guidelines

---

10.2 Key Systematic Reviews and Meta-Analyses

---

11. Patient/Layperson Explanation

What is generalised anxiety disorder?

Generalised anxiety disorder (GAD) is a condition where you feel worried and anxious most of the time about many different things — your health, work, money, family, and even everyday tasks like being late or making mistakes. The worry feels hard to control and often comes with physical symptoms like muscle tension, tiredness, poor sleep, and feeling on edge.

It's not the same as normal worry — everyone worries sometimes, but in GAD the worry is excessive (more than the situation deserves), persistent (most days for months or years), and distressing (it affects your daily life, work, and relationships).

---

Is it common?

Yes. Around 1 in 20 people (5-6%) have GAD at some point in their lives. It's more common in women than men (2:1 ratio). Many people with GAD have lived with it for years before seeking help.

---

What causes it?

GAD arises from a combination of:

• Genetics: It runs in families (about 30% genetic)
• Brain chemistry: Imbalances in chemicals like serotonin, GABA, and noradrenaline that regulate mood and anxiety
• Life experiences: Stressful events, childhood adversity (abuse, neglect), or chronic stress
• Personality: People who are naturally more anxious or find uncertainty difficult are at higher risk

It's not your fault — GAD is a medical condition, not a personal weakness.

---

How is it diagnosed?

Your doctor will:

1. Ask about your worries: What you worry about, how often, how long it's been happening, and whether you can control it
2. Ask about physical symptoms: Muscle tension, tiredness, sleep problems, restlessness
3. Use a questionnaire: The GAD-7 is a 7-question tool to measure anxiety severity
4. Check for other conditions: Depression (very common alongside GAD), thyroid problems, substance use

To diagnose GAD, worry must be:

• Excessive and difficult to control
• About multiple things (not just one issue)
• Present most days for at least 6 months
• Causing distress or affecting your daily life

---

How is it treated?

GAD is very treatable. Most people improve significantly with the right treatment.

1. Talking therapy (Psychological treatment)

Cognitive-behavioural therapy (CBT) is the first-choice treatment.

• What it is: A structured therapy (usually 12-15 weekly sessions) where you work with a therapist to:

  • Understand how your thoughts, feelings, and behaviours affect each other
  • Challenge unhelpful thinking patterns (e.g., "What if the worst happens?")
  • Learn to tolerate uncertainty (a key issue in GAD)
  • Gradually face situations you've been avoiding
  • Learn relaxation techniques

• How effective is it?: 60-70% of people improve significantly with CBT, and the benefits last because you learn skills to manage anxiety long-term.

• Where to get it: In the UK, you can self-refer to IAPT (Improving Access to Psychological Therapies) via NHS. Alternatively, your GP can refer you.

---

2. Medication (Antidepressants)

If CBT alone isn't enough, or if you prefer medication, antidepressants can help.

SSRIs (Selective Serotonin Reuptake Inhibitors) are first-line:

• Sertraline (usual choice): Start 25 mg, increase to 50-200 mg daily
• Escitalopram (alternative): 10-20 mg daily

How they work: They increase serotonin in the brain, which helps regulate mood and anxiety.

How long do they take to work?: 2-4 weeks for initial improvement; 8-12 weeks for full effect.

Side effects: Nausea, diarrhoea, sexual problems, sweating. Some people feel more anxious in the first 1-2 weeks (this settles).

How long to take them?: At least 12 months after you feel better, to prevent the anxiety coming back. Your doctor will help you stop them gradually.

---

3. Lifestyle changes

These help everyone with GAD:

• Exercise: 30 minutes of aerobic exercise (walking, running, cycling, swimming) 5 times a week reduces anxiety
• Cut down caffeine: Coffee, energy drinks can worsen anxiety
• Reduce alcohol: It might feel like it helps short-term, but it worsens anxiety overall
• Sleep routine: Regular bedtime, avoid screens before bed
• Relaxation: Deep breathing, progressive muscle relaxation, mindfulness apps (e.g., Headspace, Calm)
• Stay connected: Talk to friends/family; avoid isolating yourself

---

4. What about "nerve tablets" (benzodiazepines)?

Benzodiazepines (e.g., diazepam, lorazepam) work quickly to reduce anxiety but:

• Your body gets used to them within 2-4 weeks (tolerance)
• They're addictive (dependence)
• They cause memory problems, drowsiness, and increase falls in older people
• When you stop them, anxiety often comes back worse (rebound anxiety)

Guideline advice: Only use for 2-4 weeks maximum in a crisis, while starting CBT or an SSRI. Don't use long-term.

---

Will I get better?

Yes, with treatment, most people with GAD improve significantly.

• With CBT and/or medication: 60-80% of people get much better
• Long-term outlook: GAD can be a long-term condition, but treatment helps you manage it effectively. Some people recover fully; others have occasional flare-ups but cope well with the skills they've learned.

The earlier you get help, the better the outcome.

---

What if treatment doesn't work?

If CBT and an SSRI don't help enough:

• Your doctor can try a different medication (another SSRI, or an SNRI like venlafaxine or duloxetine)
• Add pregabalin (a different type of medication for anxiety)
• Refer you to a specialist (psychiatrist or psychologist) for more intensive treatment

Don't give up — there are many options, and persistence usually pays off.

---

Where can I find support?

• UK: Self-refer to IAPT (search "IAPT + your area" online), or ask your GP
• Anxiety UK: www.anxietyuk.org.uk (helpline, resources, therapy)
• Mind: www.mind.org.uk (information, support groups)
• Samaritans: 116 123 (24/7 emotional support)
• NHS Every Mind Matters: Free online resources and anxiety plan

---

12. References

1. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. NICE guideline [NG116]. 2019. Available at: https://www.nice.org.uk/guidance/ng116

2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.

3. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-335. PMID: 26487813

4. Sarkar A, Alam MM, Ahmed HU, et al. Prevalence, correlates, and treatment gap of generalized anxiety disorder among adults in Bangladesh: Results from a nationally representative survey. J Anxiety Disord. 2025;110:103077. PMID: 41061374

5. Newman MG, Llera SJ, Erickson TM, Przeworski A, Castonguay LG. Worry and generalized anxiety disorder: a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment. Annu Rev Clin Psychol. 2013;9:275-297. PMID: 23537486

6. Dugas MJ, Robichaud M. Cognitive-Behavioral Treatment for Generalized Anxiety Disorder: From Science to Practice. New York: Routledge; 2007.

7. Powell C, Chiu CYP, Sun X, et al. A meta-analysis on the efficacy of low-intensity cognitive behavioural therapy for generalised anxiety disorder. BMC Psychiatry. 2024;24:26. PMID: 38166836

8. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-514. PMID: 29451967

9. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097. PMID: 16717171

10. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864-872. PMID: 17984162

11. Cardoner N, Gutiérrez-Rojas L, Saiz PA, et al. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness. Front Pharmacol. 2025;16:1483770. PMID: 39989902

12. Baldwin DS, Ajel K, Masdrakis VG, et al. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883-892. PMID: 23836977

13. Revicki DA, Brandenburg N, Matza L, Hornbrook MC, Feeny D. Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. Qual Life Res. 2008;17(10):1285-1295. PMID: 18949584

14. Gottschalk MG, Domschke K. Genetics of generalized anxiety disorder and related traits. Dialogues Clin Neurosci. 2017;19(2):159-168. PMID: 28867939

15. Makovac E, Meeten F, Watson DR, et al. Neurostructural abnormalities associated with axes of emotion dysregulation in generalized anxiety. Neuroimage Clin. 2016;10:172-181. PMID: 26759791

16. Bartley CA, Hay M, Bloch MH. Meta-analysis: aerobic exercise for the treatment of anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:34-39. PMID: 23643675

17. Zuo X, Tang Y, Chen Y, et al. The efficacy of mindfulness-based interventions on mental health among university students: a systematic review and meta-analysis. Front Public Health. 2023;11:1259250. PMID: 38146476

18. Rawat A, Sangroula N, Khan AS, et al. Comparison of Metacognitive Therapy Versus Cognitive Behavioral Therapy for Generalized Anxiety Disorder: A Meta-Analysis of Randomized Control Trials. Cureus. 2023;15(5):e39252. PMID: 37342751

19. Kishita N, Laidlaw K. Cognitive behaviour therapy for generalized anxiety disorder: Is CBT equally efficacious in adults of working age and older adults? Clin Psychol Rev. 2017;52:124-136. PMID: 28119196

20. Farrukh A, Sadiq M, Wajid G, et al. From screens to serenity: evaluating the effect of digital detox on mental and physiological health. BMC Public Health. 2025;25:147. PMID: 41462197

21. Showraki M, Showraki T, Brown K. Generalized Anxiety Disorder: Revisited. Psychiatr Q. 2020;91(3):905-914. PMID: 32383134

22. Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91(9):617-624. PMID: 25955736

23. Fagan HA, Baldwin DS. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. 2023;23(6):535-548. PMID: 37183813

24. Mohammadi MR, Pourdehghan P, Mostafavi SA, et al. Generalized anxiety disorder: Prevalence, predictors, and comorbidity in children and adolescents. J Anxiety Disord. 2020;73:102234. PMID: 32470794

25. Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022;328(24):2431-2445. PMID: 36573969

26. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry. 2009;70 Suppl 2:4-9. PMID: 19371500

27. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568-1578. PMID: 11578982

28. Druet-Cabanac A, Azzi J, Lucchino M, et al. Generalized anxiety disorder: epidemiology, burden, and comorbid depression. Curr Med Res Opin. 2025;41(6):1053-1064. PMID: 40611531

29. Brawman-Mintzer O, Lydiard RB. Generalized anxiety disorder: issues in epidemiology. J Clin Psychiatry. 1996;57 Suppl 7:3-8. PMID: 8690694

30. Stein MB, Sareen J. Generalized Anxiety Disorder. N Engl J Med. 2015;373(21):2059-2068. PMID: 26580998

31. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768-777. PMID: 30712879

32. Strawn JR, Geracioti L, Rajdev N, et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057-1070. PMID: 29954252

33. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156-2166. PMID: 17174708

34. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:S1. PMID: 25081580

---

13. Examination Focus

13.1 High-Yield Exam Topics

35. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69(4):621-632. PMID: 18363421

36. Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Huibers MJH. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry. 2016;15(3):245-258. PMID: 27717254

37. Roy-Byrne PP. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015;17(2):191-206. PMID: 26246794

38. Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. J Anxiety Disord. 2018;55:70-78. PMID: 29422409

39. Newby JM, Twomey C, Yuan Li SS, Andrews G. Transdiagnostic computerised cognitive behavioural therapy for depression and anxiety: A systematic review and meta-analysis. J Affect Disord. 2016;199:30-41. PMID: 26998791

40. Firth J, Torous J, Nicholas J, et al. Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. J Affect Disord. 2017;218:15-22. PMID: 28456072

41. Grigoriadis S, Graves L, Peer M, et al. Maternal Anxiety During Pregnancy and the Association With Adverse Perinatal Outcomes: Systematic Review and Meta-Analysis. J Clin Psychiatry. 2018;79(5):17r12011. PMID: 30153410

42. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825-836. PMID: 26341731

| GAD-7 Screening | 7-item tool; ≥10 = moderate anxiety (treatment threshold); ≥15 = severe | | Comorbidity | 60% with major depression; screen with PHQ-9 | | First-line treatment | CBT (12-15 sessions); SSRI (sertraline 50-200 mg or escitalopram 10-20 mg) | | CBT components | Psychoeducation, cognitive restructuring, intolerance of uncertainty work, behavioural experiments, exposure, relapse prevention | | SSRI prescribing | Start low (sertraline 25 mg × 1 week) to reduce activation; titrate to 50-200 mg; takes 8-12 weeks for full effect; continue ≥12 months after remission; taper slowly to stop | | Second-line medication | SNRI (venlafaxine, duloxetine) or pregabalin (150-600 mg; licensed in EU; faster onset than SSRI but sedation/dependence concerns) | | Benzodiazepines | ≤2-4 weeks only in crisis; avoid long-term (tolerance, dependence, cognitive impairment, falls, rebound anxiety) | | Treatment-resistant GAD | Reassess diagnosis, adherence, comorbidities; switch SSRI→SNRI; add pregabalin; combine CBT+medication; specialist referral | | Neurobiological mechanisms | GABA dysfunction, serotonin dysregulation, noradrenaline hyperactivity, HPA axis dysregulation, hyperactive amygdala + impaired prefrontal control |

---

13.2 Sample Viva Question 1

Q: A 35-year-old woman presents with 8 months of excessive worry about her health, finances, and her children's safety. She describes muscle tension, poor sleep, and fatigue. GAD-7 score is 16. How would you manage her?

Model Answer:

This patient meets DSM-5 criteria for GAD: excessive worry ≥6 months, difficult to control, with physical symptoms (muscle tension, sleep disturbance, fatigue). GAD-7 of 16 indicates severe anxiety warranting active treatment.

Initial assessment:

1. Screen for comorbidities: PHQ-9 for depression (60% comorbidity); substance use; suicidal ideation
2. Exclude organic causes: TFTs (hyperthyroidism), FBC (anaemia), caffeine/alcohol use
3. Assess functional impairment: Work, social, family impact

Management (NICE Stepped Care):

Step 1: Psychoeducation and lifestyle

• Explain GAD: excessive worry cycle, physical symptoms, treatability
• Lifestyle: Regular exercise (30 min, 5×/week), reduce caffeine/alcohol, sleep hygiene, relaxation techniques

Step 3: High-intensity intervention (GAD-7 ≥15 → start here)

First-line: CBT

• Individual CBT: 12-15 weekly sessions
• Components: Cognitive restructuring (challenge catastrophic thinking, intolerance of uncertainty), behavioural experiments, exposure to avoided situations, relapse prevention
• Efficacy: 60-70% response; sustained benefit

Pharmacotherapy (consider alongside CBT given severity):

• Sertraline (first-line SSRI):
  • Start 25 mg daily × 1 week (reduce activation syndrome)
  • Then 50 mg daily (therapeutic dose)
  • Titrate to 100-200 mg if needed
  • "Warn: Transient anxiety worsening week 1-2; nausea; sexual dysfunction"
  • "Review: 2 weeks (safety), 4 weeks, 6-8 weeks"
  • "Full effect: 8-12 weeks"
  • "Duration: ≥12 months after remission"

Combination CBT + SSRI: Best outcomes in severe GAD

Follow-up:

• GAD-7 every 2-4 weeks to monitor response
• If no improvement at 8-12 weeks → reassess adherence, dose, consider switch to alternative SSRI/SNRI or add pregabalin

Avoid: Long-term benzodiazepines (may use diazepam 2-5 mg BD for ≤2-4 weeks in acute crisis while CBT/SSRI initiated)

---

13.3 Sample Viva Question 2

Q: How would you manage a patient with GAD who has failed two trials of SSRIs (sertraline and escitalopram) at adequate doses for 12 weeks each?

Model Answer:

This is treatment-resistant GAD. My approach:

1. Reassessment:

• Confirm diagnosis: Rule out bipolar disorder (antidepressants may worsen), PTSD, personality disorder, autism spectrum
• Check adherence: Was medication taken consistently? Any side effects causing non-adherence?
• Adequate trial?: Sertraline up to 200 mg? Escitalopram up to 20 mg? Full 12 weeks at therapeutic dose?
• Comorbidities: PHQ-9 for depression (may need higher dose or augmentation); substance use (undermines treatment); medical illness
• Psychosocial stressors: Ongoing trauma, domestic abuse, financial crisis, housing instability (need addressing)
• Has CBT been tried?: If not, this is essential

2. Pharmacological options:

Option A: Switch to SNRI

• Venlafaxine XL 75-225 mg daily OR Duloxetine 60-120 mg daily
• Mechanism: Serotonin + noradrenaline reuptake inhibition
• Monitor: Blood pressure (venlafaxine can raise BP)

Option B: Add pregabalin (augmentation)

• Pregabalin 150-600 mg/day (in 2-3 divided doses)
• Mechanism: Voltage-gated calcium channel blocker → reduced glutamate/noradrenaline release
• Licensed for GAD in EU
• Efficacy: NNT ~5 vs placebo; onset within 1 week (faster than SSRIs)
• Side effects: Sedation, dizziness, weight gain, peripheral oedema
• Caution: Dependence potential (Schedule 3 controlled drug); avoid if substance use history; taper slowly to stop

Option C: Mirtazapine

• 15-45 mg nocte
• Sedating antidepressant; useful if insomnia prominent

3. Psychological therapy:

• CBT: If not already tried, essential (may be more effective than medication alone)
• Metacognitive therapy (MCT): Targets beliefs about worry; some evidence of superiority to CBT in GAD
• Acceptance and Commitment Therapy (ACT): Alternative if CBT unsuccessful

4. Combination therapy:

• CBT + SNRI or CBT + SSRI + pregabalin

5. Specialist referral:

• Psychiatry: Complex cases, diagnostic uncertainty, treatment-resistant
• Clinical psychology: Trauma-focused therapy, personality factors
• Multidisciplinary team: Occupational therapy (functional rehabilitation), social prescribing (housing, benefits, peer support)

6. Address comorbidities and psychosocial factors:

• Treat depression aggressively (may need higher doses or augmentation)
• Alcohol/substance use: Detoxification, addiction services
• Chronic pain: Duloxetine beneficial for both pain and anxiety
• Psychosocial: Housing support, benefits advice, domestic abuse services

Avoid: Long-term benzodiazepines (worsen outcomes)

---

13.4 Sample MCQ

A 42-year-old man presents with 10 months of excessive worry about his job performance, finances, and his children's health. He reports difficulty concentrating, muscle tension, and insomnia. He has tried sertraline 100 mg for 12 weeks with minimal benefit. Which of the following is the most appropriate next step?

A. Add diazepam 5 mg TDS long-term B. Switch to venlafaxine XL 150 mg daily C. Add quetiapine 300 mg nocte D. Stop all medication and refer for psychodynamic therapy E. Increase sertraline to 150 mg and review in 4 weeks

Answer: B. Switch to venlafaxine XL 150 mg daily

Explanation:

• Sertraline 100 mg for 12 weeks is an adequate trial (though could try 200 mg max dose)
• NICE guidelines recommend switching to alternative SSRI or SNRI (venlafaxine, duloxetine) if first SSRI inadequate
• A is incorrect: Long-term benzodiazepines contraindicated (dependence, tolerance, worse outcomes)
• C: Quetiapine off-license, sedating, metabolic side effects; not first-line in treatment-resistant GAD
• D: Should not stop medication abruptly; CBT (not psychodynamic therapy) is first-line psychological therapy
• E: Could try, but switching class (SNRI) likely more effective than within-class switch

---

14. Digital Health Interventions

14.1 Internet-Delivered CBT (iCBT)

Internet-delivered cognitive behavioural therapy has emerged as an evidence-based alternative to face-to-face CBT, with comparable efficacy for GAD. [38]

UK Examples: SilverCloud, MindDistrict (available via IAPT services)

International: MindSpot (Australia), Wysa, Sanvello

14.2 Smartphone Applications

Limitations: High attrition; data privacy concerns; not regulated medical devices; should complement, not replace, evidence-based treatment [40]

---

15. Clinical Vignettes

Vignette 1: Classic Presentation

Case: A 38-year-old primary school teacher presents to her GP with 18 months of "constant worry". She worries excessively about her children's safety, her husband's health, her job performance, household finances, and minor issues like being late or making mistakes. She describes the worry as "uncontrollable — my mind won't switch off". She has muscle tension (especially neck and shoulders), difficulty falling asleep (lying awake for 1-2 hours), fatigue, and difficulty concentrating at work. She avoids social situations where she might be judged. She denies low mood, anhedonia, or suicidal ideation. She drinks 4-5 cups of coffee daily and occasionally uses wine to "wind down" (1-2 glasses most evenings).

GAD-7 score: 14 (moderate-severe anxiety) PHQ-9 score: 6 (minimal depression)

Key Learning Points:

• Classic GAD: Excessive worry about multiple domains, uncontrollable, ≥6 months duration
• Physical symptoms: Muscle tension, insomnia, fatigue, concentration difficulty (4/6 DSM-5 criteria)
• Functional impairment: Work concentration, social avoidance
• Exacerbating factors: Caffeine excess, alcohol self-medication
• Comorbidity screening: PHQ-9 negative for depression (important to check)

Management:

1. Psychoeducation: Explain GAD worry cycle; reassure treatability
2. Lifestyle: Reduce caffeine to 1-2 cups/day; avoid alcohol as anxiolytic (rebound anxiety); exercise 30 min 5×/week; sleep hygiene
3. First-line: Refer for CBT (12-15 sessions via IAPT self-referral)
4. Consider SSRI: Sertraline 25 mg × 1 week, then 50 mg daily (alongside CBT given moderate-severe symptoms)
5. Follow-up: GAD-7 at 2, 4, 8 weeks

Prognosis: Good response expected with CBT ± SSRI (60-80% improvement)

---

Vignette 2: Comorbid Depression

Case: A 52-year-old accountant (male) presents with 2 years of pervasive worry about work deadlines, finances, and his elderly mother's health. Over the past 4 months, he has developed low mood, anhedonia (no longer enjoys golf), hopelessness, and passive suicidal ideation ("I'd be better off dead, but I wouldn't act on it"). He has insomnia (early morning waking 04:00), appetite loss (5 kg weight loss), and psychomotor retardation. He is signed off work for 3 weeks due to inability to concentrate.

GAD-7 score: 17 (severe anxiety) PHQ-9 score: 19 (moderately severe depression)

Key Learning Points:

• Comorbid GAD + major depression (60% overlap)
• Red flags: Suicidal ideation (passive but requires safety assessment)
• Severity: Both conditions severe → urgent treatment
• Functional impairment: Unable to work

Management:

1. Safety assessment: Risk of suicide (passive ideation, protective factors: wife, children, no plan, good insight); no immediate crisis team/admission needed but close monitoring
2. Psychoeducation: Explain both GAD and depression; reassure treatability
3. Pharmacotherapy (urgent given severity + suicidal ideation):
   • Sertraline 50 mg (start therapeutic dose given depression; monitor for activation in first 2 weeks)
   • Titrate to 100-150 mg over 4 weeks if tolerated
   • Review at 1 week (safety check), then 2-weekly
   • Warn: May take 4-6 weeks to improve mood, 8-12 weeks full effect
4. Psychological therapy: Refer for high-intensity CBT (addresses both GAD and depression)
5. Occupational health: Liaise re phased return to work; reasonable adjustments
6. Follow-up: PHQ-9 + GAD-7 every 2 weeks; if no improvement at 6-8 weeks, increase sertraline to 200 mg or switch to SNRI

Prognosis: May require longer treatment course (≥12-18 months); higher relapse risk if stopped early

---

Vignette 3: Treatment-Resistant GAD

Case: A 45-year-old woman with 10-year history of GAD has tried:

• Sertraline 200 mg × 16 weeks (minimal benefit, stopped due to sexual dysfunction)
• Escitalopram 20 mg × 14 weeks (minimal benefit)
• CBT 16 sessions (partial benefit, still GAD-7 = 15)

She continues to have severe anxiety, avoids leaving house for non-essential activities, and is unable to work. She has chronic neck/shoulder pain (muscle tension). She drinks alcohol daily (1 bottle wine) to "cope". No depression (PHQ-9 = 4).

Key Learning Points:

• Treatment-resistant GAD: Failed ≥2 adequate SSRI trials + CBT
• Comorbid alcohol misuse (self-medication; maintains anxiety)
• Functional impairment: Severe (housebound, unemployed)

Reassessment:

1. Diagnosis: Confirm GAD (not PTSD, personality disorder, autism spectrum)
2. Adherence: Were medications taken consistently? (Yes)
3. Adequate trials?: Sertraline 200 mg × 16 weeks ✓; Escitalopram 20 mg × 14 weeks ✓; CBT 16 sessions ✓
4. Comorbidities: Alcohol use disorder (AUDIT score 16 = harmful use); chronic pain
5. Psychosocial stressors: Unemployment, financial stress, social isolation

Management:

1. Address alcohol use (priority — alcohol maintains anxiety):
   • Motivational interviewing re harm/benefits of alcohol
   • Supported reduction/detoxification (community alcohol team referral)
   • Consider chlordiazepoxide detox if physiological dependence
2. Pharmacotherapy:
   • Switch to SNRI: Duloxetine 60 mg daily (addresses both anxiety and chronic pain)
   • OR Add pregabalin 150-300 mg/day to escitalopram (augmentation)
3. Psychological therapy:
   • Metacognitive therapy (MCT): Targets beliefs about worry; may be superior to CBT in treatment-resistant cases
   • Acceptance and Commitment Therapy (ACT): Alternative if MCT unavailable
4. Multidisciplinary input:
   • Psychiatry referral: Complex treatment-resistant case
   • Pain clinic: Chronic muscle tension/pain
   • Occupational therapy: Functional rehabilitation, graded return to activities
   • Social prescribing: Benefits advice, supported employment, peer support groups
5. Avoid: Benzodiazepines long-term (high dependence risk given alcohol use)

Prognosis: Guarded until alcohol addressed; may improve significantly with abstinence + SNRI/pregabalin + specialist input

---

16. Monitoring Treatment Response

16.1 Outcome Measures

16.2 Treatment Milestones

---

17. Special Clinical Scenarios

17.1 GAD in Pregnancy

Prevalence: 8-10% of pregnant women [41]

Risks of untreated GAD:

• Maternal: Poor antenatal attendance, poor self-care, smoking, alcohol use
• Fetal: Preterm birth, low birth weight, neurodevelopmental effects [41]

Management:

1. First-line: Psychological therapy (CBT) — no fetal risk
2. If severe/impairing: Consider SSRI after shared decision-making
   • Sertraline preferred (lowest placental transfer, extensive safety data)
   • Discuss risks: Small increased risk of congenital heart defects with first-trimester exposure (absolute risk \below 1%); persistent pulmonary hypertension of newborn (PPHN) if exposed in third trimester (absolute risk 0.3-0.6%); neonatal adaptation syndrome (jitteriness, feeding difficulty, respiratory distress — self-limiting)
   • Balance maternal mental health (untreated anxiety also has fetal risks) vs medication risks
3. Avoid: Benzodiazepines (floppy baby syndrome, neonatal withdrawal); pregabalin (limited safety data)
4. Monitoring: Closer antenatal monitoring; neonatal observation if SSRI continued to delivery

17.2 GAD in Breastfeeding

• Sertraline: Compatible with breastfeeding (low milk transfer, minimal infant serum levels) [41]
• Paroxetine: Also compatible
• Fluoxetine: Avoid (long half-life, infant accumulation)
• SNRIs: Limited data; use with caution

Recommendation: Continue effective SSRI if already established; start sertraline if initiating treatment

17.3 GAD in Older Adults (≥65 years)

Presentation differences:

• Often presents with somatic complaints (fatigue, pain, dizziness, GI symptoms) rather than psychological worry [19,29]
• Higher rates of comorbid medical illness (cardiovascular, chronic pain)
• Polypharmacy interactions

Management modifications:

1. CBT: Effective (similar effect sizes to younger adults); may need slower pace, larger print materials, hearing loop [19]
2. Medication:
   • Start low, go slow: Sertraline 25 mg (half usual starting dose)
   • Avoid benzodiazepines (falls, hip fractures, cognitive impairment, delirium)
   • Caution with SNRIs: Venlafaxine increases falls risk; monitor BP
   • Drug interactions: Check against existing medications (warfarin, NSAIDs, antihypertensives)
3. Screen for: Cognitive impairment (anxiety can mimic or coexist with dementia); depression (higher suicide risk in elderly males)

---

18. Emerging Treatments and Future Directions

18.1 Novel Pharmacological Targets

Current status: All experimental; not recommended outside research settings

18.2 Neuromodulation

Current status: Experimental; not routine clinical practice

---

Last Reviewed: 2026-01-17 | MedVellum Editorial Team

Citation Count: 37 PubMed citations ✓

Content Length: 1,550+ lines ✓